Introduction {#s1}
============

Endoscopic submucosal dissection (ESD) is a promising method for the resection of superficial gastric neoplasms^[@r1],[@r2],[@r3],[@r4])^. Historically, proton pump inhibitor (PPI) injection has been used in the perioperative period of ESDs based on peptic ulcer treatment. However, to date, there has been little evidence as to the efficacy of PPI injection in this period^[@r5])^.

Vonoprazan is an orally administered active potassium-competitive acid blocker (P-CAB). It has been considered a potential alternative to PPIs for the treatment of acid-related diseases^[@r6])^. Recently, several studies have investigated the efficacy of vonoprazan in gastric ESD-derived ulcers^[@r7],[@r8],[@r9],[@r10],[@r11])^. Importantly, as compared with PPI therapy, P-CAB therapy achieved comparable or superior efficacy in ulcer healing. To date, the utility of vonoprazan for gastric ESD has not been completely established. However, compared with the commonly used PPIs, the effects of vonoprazan can be expected to suppress acid secretion and rapidly increase gastric pH compared with PPIs.

The most serious adverse event in ESD is postoperative bleeding, which can take place within the first two weeks^[@r12],[@r13],[@r14])^. Specifically, the incidence of postoperative bleeding has been reported to be around 4.5%^[@r15])^. However, artificial ulcers induced by ESD are treated with PPIs for 4--8 weeks, according to the peptic ulcer therapy protocol.

Therefore, in the present study, we evaluated the improvement of procedure outcomes and the prevention of adverse events including postoperative bleeding in patients treated with PPI injection followed by P-CAB administration or P-CAB administration alone. Data were evaluated using propensity score matching (PSM) analysis^[@r16])^.

Methods {#s2}
=======

Participants
------------

We enrolled a total of 270 consecutive patients with superficial gastric neoplasms. Individuals were treated by ESD at the Hiraka General Hospital between April 2015 and December 2018. Data were collected from the hospital database and retrospectively reviewed. Patients included in the study were those who underwent gastric ESD in our institution for cancers adhering to the absolute and expanded criteria^[@r17],[@r18])^ established by endoscopy. Exclusion criteria were as follows: history of prior surgery (n=4), antithrombotic therapy (n=49), prior use of acid suppressant (n=20), and other acid suppressants for ESD (n=47). Finally, a total of 150 patients were included. Patients were intravenously infused with omeprazole (20 mg b.i.d.) for the first two days following the oral administration of 20 mg of vonoprazan for 12 days (PPI group; n=80), who were treated between April 2015 and December 2016. Alternatively, patients were administered 20 mg vonoprazan alone for 14 days (P-CAB group; n=70), who were treated between January 2017 and December 2018 ([Figure 1](#fig_001){ref-type="fig"}Figure 1Study protocol.). *Helicobacter pylori* (*H. pylori*) infection was assessed in all patients by at least one of the following three methods: (1) the anti-*Hp* immunoglobulin G serological test, (2) the rapid urease test, or (3) the ^13^C-urea breath test. Tumors were categorized according to their location (i.e., upper \[U\], middle \[M\], or lower third \[L\]) and circumference (i.e., anterior wall \[A\], posterior wall \[P\], greater curvature \[G\], or lower curvature \[L\]) in the stomach. Atrophic gastritis patterns were evaluated using the Kimura and Takemoto classification^[@r19])^.

Study outcomes
--------------

The outcomes of the study were as follows: intragastric pH levels prior to ESD, the frequency of intraoperative major bleeding, procedure time, *en bloc* resection rate, curability, ulcer reduction rate 14 days after ESD, and adverse events. Specifically, gastric juice was collected using an irrigation tube (PW-6P-1; Olympus Optical, Tokyo, Japan). pH was determined using a test paper (range pH 3.4--6.4; Advantec Toyo, Tokyo, Japan). Major intraoperative bleeding was defined as extensive bleeding requiring the use of hemostatic forceps (Coagrasper; FD-411QR; Olympus) to achieve complete hemostasis^[@r20])^. Procedure times were recorded as the time frame between marking and completion of tumor removal. Ulcer reduction rate was determined using the following formula: (1 − ulcer area on post-ESD day 14 / ulcer area on post-ESD day 0) ×100 (%). Of note, the ulcer area was calculated by the following formula: (major axis × minor axis) (mm^2^). They were determined by means of a bendable endoscopic measuring device (M2-3; Olympus). Adverse events included perforation during the procedure and postoperative bleeding. We defined perforation as when we could visualize endoscopically either an extramural organ or fat outside the stomach's muscle layer and observe free air by abdominal radiography or computed tomography during or within four weeks post-ESD. Postoperative bleeding was defined as either a decrease in blood hemoglobin levels \>2 g/dL or clinical evidence of bleeding due to the ESD procedure, combined with the occurrence of hematemesis and melena, the presence of bleeding on endoscopy, or a combination of unstable vital signs from completion to 4 weeks after the procedure.

ESD
---

ESD techniques have been extensively described in detail elsewhere^[@r4])^. The procedure was performed with a FlushKnife-BTS (DK2625S; FUJIFILM Medical, Tokyo, Japan). A single endoscopist who performed over 600 cases of ESD executed the technique. To prevent intraoperative bleeding, the operator carefully identified blood vessels in the surgical field and thermally coagulated and subsequently cut the blood vessels (preventative coagulation). Preventative coagulation was indicated for vessels with a diameter of \>1 mm, as compared to the tip of the FlushKnife with a 0.9-mm diameter^[@r20])^. When vessels did not turn whitish after coagulation, hemostatic forceps were used. Thereafter, lesions were dissected at a deep layer of the submucosa. Following the ESD procedure, we first carefully identified the artificial ulcer base and then coagulated the exposed vessels with hemostatic forceps. Vessels were also coagulated in the absence of bleeding^[@r21])^. Measurement and histological classification were performed on the resected specimens according to the criteria of the Japanese Gastric Cancer Association^[@r22])^. Lesions were then evaluated for curability.

Follow-up
---------

We did not perform a second-look endoscopy. In absence of any complications, patients resumed food intake on post-ESD day 2. All patients were discharged within seven days following ESD. A follow-up endoscopy was performed 14 days after ESD.

PSM
---

The baseline characteristics of patients receiving ESD therapy included multiple stratification factors. Therefore, PSM was used to minimize potentially confounding factors and selection biases and to identify controls within the study-patient group. We used 10 possible confounders as matching factors. Nine variables based on previous reports were used: age, sex, comorbidity (chronic kidney disease), lesion location, lesion circumference, macroscopic type, specimen size, tumor depth, and histology^[@r20],[@r23],[@r24],[@r25],[@r26])^. Atrophic gastritis patterns were significantly different in univariate analysis. In a multivariate logistic regression analysis, the confounders were included as independent variables, while therapy with P-CAB alone was included as the dependent variable. The propensity score for therapy with P-CAB alone was calculated through logistic regression analysis. Following the estimation of the propensity score, control patients and those of the P-CAB group were matched. Optimal matching was achieved at a 1:1 ratio, and we used a caliper coefficient of 0.1 for the logit of the propensity score without replacement. Covariate balance was measured using the standardized difference, whereby an absolute standardized difference above 10% represents meaningful imbalance.

Statistical analysis
--------------------

Statistical analysis of the clinical and endoscopic data was done with the χ^2^ test for categorical data and Student's t-test for numerical data for univariate analysis. We determined both absolute differences and *P*-values. We considered *P*\<0.05 as statistically significant. All statistical analyses were performed with JMP version 12.0 (SAS Institute, Cary, NC, USA).

Ethics
------

The study was performed in accordance with the principles of the Declaration of Helsinki. The ethics committee of the Hiraka General Hospital approved the study. Written informed consent from all patients and their families was obtained to perform endoscopic submucosal dissection and publish the data.

Results {#s3}
=======

Baseline characteristics
------------------------

[Table 1](#tbl_001){ref-type="table"}Table 1Baseline characteristics of the 150 superficial gastric neoplasms that underwent ESDPPI Group (n=80)P-CAB group (n=70)*P*ASDPatient characteristicsAge, median \[range\] (y)73 \[47--88\]73 \[54--89\]0.068\*0.300SexMale/Female63/1752/180.519^†^0.105*H.pylori* statuspositive/negative/post eradication63/4/1354/2/140.693^†^0.110Atrophic gastritis patternopen/closed/none58/19/365/3/20.003^†^0.583Comorbities (positive/negative)Diabetes mellitus3/771/690.379^†^0.146Chronic kidney disease (eGFR \<30)1/797/630.017^†^0.386Liver cirrhosis0/801/690.283^†^0.170Lesion characteristicsLesion locationU/M/L13/33/3424/17/290.017^†^0.046Lesion circumferenceA/P/G/L13/22/20/257/21/17/250.190^†^0.185Macroscopic typeFlat/Depressed37/4325/450.191^†^0.215Specimen sizemean \[SD\] (mm^2^)1,706.2 \[124.41\]1,317.4 \[938.3\]0.023\*0.580Tumor depthM/SM73/762/80.585^†^0.160Histologydifferentiated/pooly differentiated73/762/80.973^†^0.069*H.pylori: Helicobacter pylori*; U: upper third; M: middle third; L: lower third of the stomach; A: anterior wall; P: posterior wall; G: greater curvature; L: lower curvature; SD: standerd deviation; ASD: Absolute standerdized difference. \*: student's t-test; †: χ^2^ test. shows the baseline characteristics for both the PPI group and the P-CAB group. We observed a significant difference in the two groups for the following characteristics: atrophic gastritis pattern (*P*=0.003), chronic kidney disease (*P*=0.017), lesion location (*P*=0.017), and specimen size (*P*=0.023). Of note, other patient characteristics and lesion characteristics were not significantly different between groups. [Table 2](#tbl_002){ref-type="table"}Table 2Matching variables after propensity score analysisPPI Group (n=43)P-CAB group (n=43)*P*ASDPatient characteristicsAge, median \[range\] (y)74 \[47--88\]73 \[54--87\]0.663\*0.094SexMale/Female31/1230/130.519^†^0.051Atrophic gastritis patternopen/closed/none39/2/238/3/20.899^†^0.099Comorbities (positive/negative)Chronic kidney disease (eGFR \<30)1/421/421.000^†^0.000Lesion characteristicsLesion locationU/M/L12/12/1912/11/200.966^†^0.021Lesion circumferenceA/P/G/L6/12/10/154/14/11/140.888^†^0.095Macroscopic typeFlat/Depressed19/2417/260.662^†^0.094Specimen sizemean \[SD\] (mm^2^)1,458.1 \[1,041.4\]1,389.5 \[1,067.35\]0.764\*0.065Tumor depthM/SM38/540/30.456^†^0.089Histologydifferentiated/pooly differentiated37/638/50.747^†^0.005*H.pylori: Helicobacter pylori*; U: upper third; M: middle third; L: lower third of the stomach; A: anterior wall; P: posterior wall; G: greater curvature; L: lower curvature; SD: standerd deviation; ASD: Absolute standerdized difference. \*: student's t-test; †: χ^2^ test. describes the matched variables and outcomes in both groups after PSM. Forty-three pairs of patients were matched and compared with regard to outcomes. The propensity score model was well-calibrated (AUC=0.77) and optimally matched (Caliper: 0.1, standardized difference \< 0.1) in terms of baseline patients and lesion characteristics in both groups.

Treatment outcomes in the P-CAB and PPI groups after PSM
--------------------------------------------------------

[Table 3](#tbl_003){ref-type="table"}Table 3Treatment outcomes after propensity score matchingPPI Group (n=43)P-CAB group (n=43)*P*Intra-gastric pH level 6.4 (%)43/43 (100.0)43/43 (100.0)1.000^†^Frequency of major bleedingmedian \[range\] (times)0 \[0--4\]0 \[0--5\]0.527\*Procedure timemean \[SD\] (min.)72.37 \[51.78\]72.93 \[41.37\]0.956\**En bloc* resection rate (%)43/43 (100.0)43/43 (100.0)1.000^†^Curability (eCura)A/B/C1/C232/10/0/135/7/0/10.717^†^Ulcer reduction rate 14 days after ESDmean \[SD\] (%)75.32 \[11.30\]78.76 \[13.18\]0.196\*Adverse events (positive/negative)Perforation (%)0/43 (0.0)0/43 (0.0)1.000^†^Postoperative bleeding (%)1/43 (2.3)0/43 (0.0)0.315^†^SD: standerd deviation; \*: student's t-test; †: χ^2^ test. describes outcomes in both groups. All cases had indicated intragastric pH levels of 6.4 pre-ESD. The ulcer size reduction at 14 days post-ESD was similar between groups (mean \[SD\]; 75.32% \[11.30\] in the PPI group vs. 78.76% \[13.18\] in the P-CAB group, *P*=0.196). Postoperative bleeding occurred in 1 (2.3%) patient in the PPI group and in 0 (0.0%) patients in the P-CAB group (*P*=0.315). Other outcomes (frequency of intraoperative major bleeding, procedure time, *en bloc* resection rate, curability, and perforation) were the same in both groups, specifically with a low incidence of adverse events. No treatment-related deaths were observed.

Discussion {#s4}
==========

The aim of the present study was to assess the effectiveness of PPI injection compared to P-CAB administration alone during the perioperative period of gastric ESD using PSM. We demonstrate that there is no significant difference between PPI injection and vonoprazan tablets alone in terms of treatment outcomes and adverse events.

Acid-suppressing agents have been used mainly to prevent postoperative bleeding post-ESD.In an earlier study, Berstad reported that digestion of fibrin clots by gastric juice indicated no activity at pH \>4^[@r27])^. Gastric acid inhibition to maintain a neutral pH could stabilize blood clots and prevent recurrent bleeding^[@r28],[@r29])^. Previous studies have reported that PPIs were more effective than histamine-2-receptor antagonists (H~2~RAs) in controlling bleeding in patients undergoing ESD^[@r30])^. Therefore, the administration of PPIs has become a standard therapy to manage iatrogenic gastric ulcers post-ESD. On the contrary, bleeding events mostly occurred within 24 hours and extended up to 2 weeks post-ESD^[@r14])^. Therefore, the rapid inhibition of gastric acid secretion is necessary via acid-suppressing agents. However, previous studies have revealed a delay in the sustained reduction of acid secretion with PPIs. Maximum efficacy was typically reached only after 3--5 days of standard dosing^[@r31])^. Clinically, such controversial data has created concerns over gastric ESD. Uedo *et al.* reported that administration of rabeprazole 1 day before ESD might be sufficient in increasing intragastric pH at the time of ESD^[@r32])^. In contrast, One *et al.* showed no additional benefit in the 1-day preoperative administration of omeprazole and a prior increase of intragastric pH in preventing bleeding post-ESD^[@r33])^.

For patients with upper gastrointestinal bleeding, intravenous injection of omeprazole was developed in 2001, while the injection of lansoprazole was developed in 2006. A single infusion of PPIs is known to quickly raise intragastric pH to above 4^[@r34])^. As a consequence, it has historically been used for gastric ESD, similar to hemorrhagic peptic ulcer treatment. However, there is little evidence available to date in its use in the perioperative period of ESD. Ishido *et al.* reported a similar effectiveness in the 1-day preoperative administration of lansoprazole tablets compared to intravenous lansoprazole in a randomized controlled trial (RCT)^[@r5])^ for bleeding prevention post-ESD.

The novel therapeutic agent vonoprazan rapidly suppresses gastric acid secretion^[@r6])^. The drug is reported to achieve steady-state acid levels on the first day. Additionally, it raises intragastric pH above 4 by 4 hours after the first dose^[@r6],[@r35])^. In the present study, the first administration of omeprazole injection or vonoprazan was performed 8 hours prior to the ESD procedure. All the cases in both the PPI and the P-CAB group had a pH \>6.4 at the beginning of ESD.

The following are the medication costs for 14 days of treatment in the present study. Specifically, total costs were estimated by the Japan Ministry of Health, Labour and Welfare in 2018 to be 4,039.2 yen for the PPI group (2 days of omeprazole injection and 12 days of vonoprazan tablets) and 2,822.4 yen for the P-CAB group (14 days of vonoprazan tablets). Importantly, treatment with P-CAB alone is only 70% of the cost of the standard PPI treatment. In addition, intravenous infusion of omeprazole (b.i.d.) would not be necessary in the P-CAB group for the first two days. Therefore, we believe that because of low costs, decreased effort, and safety, P-CAB administration alone is advantageous compared with PPI injection.

The present study has several limitations as follows. Firstly, it was done in a single institution and only a relatively small number of patients were retrospectively enrolled. Secondly, only an experienced endoscopist performed all the ESD procedures. However, we believe that a consistent level of technical expertise and identical therapeutic strategies between operators could positively influence the assessment of treatment outcomes and adverse events. Finally, we did not enroll patients on antithrombotic therapy in this study. In the future, a multicenter large-scale prospective RCT with or without antithrombotic therapy will be warranted to determine the influence of oral administration of P-CAB alone on the effects and outcomes of ESD.

Conclusion {#s5}
==========

Oral administration of P-CAB alone was as effective as PPI injection. We observed a low incidence of adverse events. Therefore, we believe that PPI injection might be safely omitted from the procedure of gastric ESD considering its cost and high labor.
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